

Fig. 1

10080272-092302



卷之三




Fig. 2




Fig. 7

100080272-092302




Fig. 4

10080272-092302





Fig. 5

10080272 - 092302



2002601220300T






Fig. 1

10080272-092302




Fig. 8

10080272 - 092302

9/30




Fig. 9

10080272-0922302

202560" 2/200001




Fig. III




Fig. 11




Fig. 1d




Fig. 13

10030272 · 09230261

14/30




Fig. 14




Fig. 15

10080272 - 092302





Fig. 16


16/30





1000260-2720000

Consistency of RBC product performance with numerous donors



18/30



Large Volume Transfected Fibroblasts Are Viable
and Express Functional Transgene in vivo




Fig. 19

202260 2720800T




Fig. 20

19/30




Fig. 21




Fig. 22

10080272-092302

20/30




Fig. 23A




Fig. 23B

21/30




Fig. 24A




Fig. 24B

1008027208002
2003027208002




Fig. 25.





Fig. 26



10080272-092302

O I P E
SEP 2 3 2002
U. S. PATENT & TRADEMARK OFFICE

24/30




Fig. 28





Fig. 29

10080272 - 092302





202260 2420800T



26/30




Fig. 30B

10080272-092302




Fig. 30C




Fig. 300







Fig. 30E

Fig. 30F



10080272-092302





200260 27270001
O I P E
O I P E
U. S. PATENT & TRADEMARK OFFICE
SEP 23 2002

30/30




Fig. 32B




Fig. 32C




Fig. 32D

10080272-092302
20020272-092302